Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
CIDPChronic Inflammatory Demyelinating Polyneuropathy
Interventions
DRUG

lipoic acid

Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Collins Medical Trust

OTHER

lead

Oregon Health and Science University

OTHER